Brent Hanks
Medical Oncology · Durham, NCNPI 1568639441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,410 of the $24,350 with a category attached, or 71.5%. Novartis accounts for 99.9% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2020 at $14,161 and has fallen 99.8% since, to $26 in 2025.
Across 17 payments — averaging $1432.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$24K
- Merck$33
Across 28 payments — averaging $53,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.4M
- Sanofi US Services Inc.$55K
- Iovance Biotherapeutics, Inc.$31K
What the payments were for
- Consulting fees$3,75015%
- Speaking & faculty fees$17,41071%
- Travel & lodging$3,08813%
- Food & beverage$690%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,350 in reported general payments places this provider in the 80th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 17 | $224 |
| Dexamethasone | 14 | $210 |
| Oxycodone Hcl | 14 | $203 |
| Ondansetron Hcl | 16 | $181 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Durham
- Thomas LeblancDurham$1.7M
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Michael HarrisonDurham$161K
- Jeffrey ClarkeDurham$140K
- Sundhar RamalingamDurham$93K
- Arif KamalDurham$50K
- Nelson ChaoDurham$45K
- Laura AlderDurham$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.